Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Lirafugratinib is a covalent inhibitor of FGFR2 (IC50 = 0.003 µM).1 It is selective for FGFR2 over FGFR1, -3, and -4 (IC50s = 0.77, 0.26, and 15 µM, respectively). Lirafugratinib inhibits the proliferation of SNU-16 gastric cancer cells (IC50 = 0.002 µM). In vivo, lirafugratinib (10 mg/kg) reduces intratumoral FGFR2 phosphorylation and tumor volume in an FGFR2-amplified SNU-16 gastric cancer mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Discovery of lirafugratinib (RLY-